Day One Biopharmaceuticals Inc.: Piper Sandler Sees 267% Price Potential!
Reading Time: 3 minutes
The business model of Day One Biopharmaceuticals Inc. (DAWN) is focused on the development and commercialization of targeted therapies for people of all ages with life-threatening diseases. The company was founded with the aim of addressing the significant lack of therapeutic development in the area of pediatric cancers. OJEMDA (tovorafenib) is the company's primary commercial product and a Type II RAF kinase inhibitor. OJEMDA is approved for the treatment of patients aged 6 months and older with recurrent or refractory pediatric low-grade glioma...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
